Drug intelligence / Profile preview

Botaluma

Development stage
Phase 2
Lead developer
Pharma Research Products
Modality
Recombinant Proteins and Enzymes
Administration
Intramuscular, Intradermal, Subcutaneous
01

Overview

Botaluma is a branded botulinum toxin type A injectable neurotoxin product used for aesthetic and/or therapeutic indications, analogous to other botulinum toxin type A formulations such as Botox, although detailed public information specific to this brand is limited. Like other botulinum toxin type A preparations, it is expected to act by cleaving the synaptic protein SNAP-25 in cholinergic nerve terminals, thereby blocking acetylcholine release at the neuromuscular junction and autonomic synapses, producing a temporary chemodenervation of targeted muscles or glands and resulting in reduced muscle contraction or secretory activity. The product is formulated as a biologic protein toxin derived from Clostridium botulinum and administered in very low doses by local injection to achieve focal effects with minimal systemic exposure.

Brand names
Botaluma
02

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on Botaluma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Botaluma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call